

**Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2024-2032**

Market Report | 2024-07-01 | 147 pages | IMARC Group

**AVAILABLE LICENSES:**

- Electronic (PDF) Single User \$3899.00
- Five User Licence \$4899.00
- Enterprisewide License \$5899.00

**Report description:**

The global anti-tuberculosis therapeutics market size reached US\$ 1,445.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US\$ 2,448.5 Million by 2032, exhibiting a growth rate (CAGR) of 5.85% during 2024-2032. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by *Mycobacterium tuberculosis*. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

**Anti-Tuberculosis Therapeutics Market Trends:**

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

#### Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.

#### Disease Type Insights:

- Active TB
- Latent TB
- Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.

#### Diagnosis and Treatment Insights:

- Diagnosis
  - Blood Tests
  - Imaging Tests
  - Sputum Tests
  - Others
- Treatment
  - First-Line of Drugs
    - Isoniazid
    - Ethambutol
    - Rifampin
    - Others
  - Second-Line of Drugs
    - Thiacetazone
    - Paraaminosalicylic Acid (PAS)
    - Others
  - Others

A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicylic acid (PAS), and others), and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

others

#### End User Insights:

Hospitals  
Specialty Clinics  
Homecare  
Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.

#### Regional Insights:

North America  
United States  
Canada  
Europe  
Germany  
France  
United Kingdom  
Italy  
Spain  
Russia  
Others  
Asia Pacific  
China  
Japan  
India  
South Korea  
Australia  
Indonesia  
Others  
Latin America  
Brazil  
Mexico  
Others  
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

#### Competitive Landscape:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

#### Key Questions Answered in This Report:

How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?

What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?

What are the key regional markets?

Which countries represent the most attractive anti-tuberculosis therapeutics market?

What is the breakup of the market based on the disease type?

Which is the most attractive disease type in the anti-tuberculosis therapeutics market?

What is the breakup of the market based on the diagnosis and treatment?

Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?

What is the breakup of the market based on end user?

Which is the most attractive end user in the anti-tuberculosis therapeutics market?

What is the competitive structure of the global anti-tuberculosis therapeutics market?

Who are the key players/companies in the global anti-tuberculosis therapeutics market?

#### Table of Contents:

1	Preface
2	Scope and Methodology
2.1	Objectives of the Study
2.2	Stakeholders
2.3	Data Sources
2.3.1	Primary Sources
2.3.2	Secondary Sources
2.4	Market Estimation
2.4.1	Bottom-Up Approach
2.4.2	Top-Down Approach
2.5	Forecasting Methodology
3	Executive Summary
4	Introduction
4.1	Overview
4.2	Key Industry Trends
5	Global Anti-Tuberculosis Therapeutics Market
5.1	Market Overview
5.2	Market Performance
5.3	Impact of COVID-19
5.4	Market Forecast
6	Market Breakup by Disease Type
6.1	Active TB
6.1.1	Market Trends
6.1.2	Market Forecast
6.2	Latent TB
6.2.1	Market Trends

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.2.2 Market Forecast
- 6.3 Others
  - 6.3.1 Market Trends
  - 6.3.2 Market Forecast
- 7 Market Breakup by Diagnosis and Treatment
  - 7.1 Diagnosis
    - 7.1.1 Market Trends
    - 7.1.2 Key Segments
      - 7.1.2.1 Blood Tests
      - 7.1.2.2 Imaging Tests
      - 7.1.2.3 Sputum Tests
      - 7.1.2.4 Others
    - 7.1.3 Market Forecast
  - 7.2 Treatment
    - 7.2.1 Market Trends
    - 7.2.2 Key Segments
      - 7.2.2.1 First-Line of Drugs
        - 7.2.2.1.1 Major Types
          - 7.2.2.1.1.1 Isoniazid
          - 7.2.2.1.1.2 Ethambutol
          - 7.2.2.1.1.3 Rifampin
          - 7.2.2.1.1.4 Others
        - 7.2.2.1.2 Paraaminosalicylic Acid (PAS)
        - 7.2.2.1.3 Others
      - 7.2.2.2 Second-Line of Drugs
        - 7.2.2.2.1 Major Types
          - 7.2.2.2.1.1 Thiacetazone
          - 7.2.2.2.1.2 Paraaminosalicylic Acid (PAS)
          - 7.2.2.2.1.3 Others
        - 7.2.2.2.2 Others
      - 7.2.2.3 Others
      - 7.2.2 Market Forecast
  - 8 Market Breakup by End User
    - 8.1 Hospitals
      - 8.1.1 Market Trends
      - 8.1.2 Market Forecast
    - 8.2 Specialty Clinics
      - 8.2.1 Market Trends
      - 8.2.2 Market Forecast
    - 8.3 Homecare
      - 8.3.1 Market Trends
      - 8.3.2 Market Forecast
    - 8.4 Others
      - 8.4.1 Market Trends
      - 8.4.2 Market Forecast
  - 9 Market Breakup by Region
    - 9.1 North America
      - 9.1.1 United States
        - 9.1.1.1 Market Trends
        - 9.1.1.2 Market Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
  - 9.2.1 China
    - 9.2.1.1 Market Trends
    - 9.2.1.2 Market Forecast
  - 9.2.2 Japan
    - 9.2.2.1 Market Trends
    - 9.2.2.2 Market Forecast
  - 9.2.3 India
    - 9.2.3.1 Market Trends
    - 9.2.3.2 Market Forecast
  - 9.2.4 South Korea
    - 9.2.4.1 Market Trends
    - 9.2.4.2 Market Forecast
  - 9.2.5 Australia
    - 9.2.5.1 Market Trends
    - 9.2.5.2 Market Forecast
  - 9.2.6 Indonesia
    - 9.2.6.1 Market Trends
    - 9.2.6.2 Market Forecast
  - 9.2.7 Others
    - 9.2.7.1 Market Trends
    - 9.2.7.2 Market Forecast
- 9.3 Europe
  - 9.3.1 Germany
    - 9.3.1.1 Market Trends
    - 9.3.1.2 Market Forecast
  - 9.3.2 France
    - 9.3.2.1 Market Trends
    - 9.3.2.2 Market Forecast
  - 9.3.3 United Kingdom
    - 9.3.3.1 Market Trends
    - 9.3.3.2 Market Forecast
  - 9.3.4 Italy
    - 9.3.4.1 Market Trends
    - 9.3.4.2 Market Forecast
  - 9.3.5 Spain
    - 9.3.5.1 Market Trends
    - 9.3.5.2 Market Forecast
  - 9.3.6 Russia
    - 9.3.6.1 Market Trends
    - 9.3.6.2 Market Forecast
  - 9.3.7 Others
    - 9.3.7.1 Market Trends
    - 9.3.7.2 Market Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.4 Latin America
  - 9.4.1 Brazil
    - 9.4.1.1 Market Trends
    - 9.4.1.2 Market Forecast
  - 9.4.2 Mexico
    - 9.4.2.1 Market Trends
    - 9.4.2.2 Market Forecast
  - 9.4.3 Others
    - 9.4.3.1 Market Trends
    - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
  - 9.5.1 Market Trends
  - 9.5.2 Market Breakup by Country
  - 9.5.3 Market Forecast
- 10 Drivers, Restraints, and Opportunities
  - 10.1 Overview
  - 10.2 Drivers
  - 10.3 Restraints
  - 10.4 Opportunities
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
  - 12.1 Overview
  - 12.2 Bargaining Power of Buyers
  - 12.3 Bargaining Power of Suppliers
  - 12.4 Degree of Competition
  - 12.5 Threat of New Entrants
  - 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
  - 14.1 Market Structure
  - 14.2 Key Players
  - 14.3 Profiles of Key Players
    - 14.3.1 F. Hoffmann-La Roche Ltd.
      - 14.3.1.1 Company Overview
      - 14.3.1.2 Product Portfolio
      - 14.3.1.3 SWOT Analysis
    - 14.3.2 Lannett Company Inc.
      - 14.3.2.1 Company Overview
      - 14.3.2.2 Product Portfolio
      - 14.3.2.3 Financials
      - 14.3.2.4 SWOT Analysis
    - 14.3.3 Lupin Limited
      - 14.3.3.1 Company Overview
      - 14.3.3.2 Product Portfolio
      - 14.3.3.3 Financials
      - 14.3.3.4 SWOT Analysis
    - 14.3.4 Macleods Pharmaceuticals Limited

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

14.3.4.1 Company Overview  
14.3.4.2 Product Portfolio  
14.3.5 Otsuka Pharmaceutical Co. Ltd  
14.3.5.1 Company Overview  
14.3.5.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Anti-Tuberculosis Therapeutics Market Report by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2024-2032**

Market Report | 2024-07-01 | 147 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Electronic (PDF) Single User	\$3899.00
	Five User Licence	\$4899.00
	Enterprisewide License	\$5899.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-09

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

A large, empty rectangular box with a thin black border, intended for a signature.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)